资讯

NeOnc Technologies Holdings, Inc.: NeOnc Technologies Announces Near Completion of Phase I ...
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous ...
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer ...
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced ...
The Scientist2 天
To Fuel Their Growth, Cancer Cells Hijack Neurons
The Brain Prize 2025 went to neuro-oncologists Michelle Monje and Frank Winkler for pioneering the field of cancer n.
American Association of Individual Investors2 天
Why HUTCHMED (China) Limited’s (HCM) Stock Is Down 15.68%
Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.
CURE4 天
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...
MedPage Today on MSN5 天
Cerebrospinal Fluid Liquid Biopsy for Glioma Shows Clinical Management Potential
Circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) of patients with glioma had a high concordance with tumor DNA and ...
Ophthalmology Advisor6 天
Ocular Signs of Neurofibromatosis Type 1 Negligible After 7 Years of Age
The development of ocular signs of neurofibromatosis type 1 (NF1) is only significant in patients 7 years of age and younger.